Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Platelet Storage Pool Deficiency D010981 3 associated lipids
Thrombophilia D019851 6 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Leukocyte-Adhesion Deficiency Syndrome D018370 1 associated lipids
Neoplasms, Germ Cell and Embryonal D009373 4 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Colitis, Ischemic D017091 3 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Alabaster VA et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. 1991 Agents Actions Suppl. pmid:1793066
Heuer HO The effects of hetrazepine PAF antagonists in preclinical models of asthma. 1991 Agents Actions Suppl. pmid:1793067
Mazzoni L et al. Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. 1991 Agents Actions Suppl. pmid:1793069
Billah MM et al. Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. 1991 Agents Actions Suppl. pmid:1793070
Saeed SA et al. Inhibitory effect of oral ketotifen on ex vivo platelet activating factor-induced platelet aggregation. 1991 Agents Actions Suppl. pmid:1793071
Hoshiko K et al. Histamine(H1) antagonists and airway hyperreactivity in the guinea-pig. 1991 Agents Actions Suppl. pmid:1686527
Mest HJ et al. Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. 1992 Agents Actions Suppl. pmid:1632298
Koltai M and Braquet PG Involvement of PAF in atherogenesis. Brief review. 1992 Agents Actions Suppl. pmid:1632308
McMillan RM and Carter GW Design and development of drugs. 1991 Agents Actions Suppl. pmid:1664186
Rihoux JP The inhibiting effect of cetirizine 2 HC1 on eosinophil migration and its link to H1 blockade. 1991 Agents Actions Suppl. pmid:1675836
Page CP and Spina D The therapeutic relevance of PAF antagonists. 1989 Agents Actions Suppl. pmid:2683635
Rink TJ Stimulus-response coupling mechanisms in human platelets. 1986 Agents Actions Suppl. pmid:3028101
Baroggi N et al. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds. 1986 Agents Actions Suppl. pmid:3028108
Page CP et al. Drugs affecting pulmonary responses to platelet activating factor as novel anti-asthma drugs. 1988 Agents Actions Suppl. pmid:3051932
Muirhead EE Vasodepressor lipid of the renomedullary interstitial cells of the renal papilla is a prohormone activated by the liver. 1987 Agents Actions Suppl. pmid:3324720
Etienne A et al. Antithrombotic activity of BN 50341, a structurally new compound with anticalcic and PAF-antagonistic properties. 1986 Agents Actions Suppl. pmid:3468781
Guinot P et al. Effects of BN 52063 on PAF-acether induced weal and flare in man. 1987 Agents Actions Suppl. pmid:3479000
Lang M et al. Effects of the PAF-antagonist CV-3988 on PAF-induced changes in mucus secretion and in respiratory and circulatory variables in ferrets. 1987 Agents Actions Suppl. pmid:3479001
Codde JP et al. Effects of altered prostanoid and lyso-PAF synthesis by marine oil diets on blood pressure of salt loaded spontaneously hypertensive rats. 1987 Agents Actions Suppl. pmid:3481207
Braquet P et al. The role of PAF-acether in anaphylaxis demonstrated with the use of the antagonist BN 52021. 1987 Agents Actions Suppl. pmid:3314418
Morley J et al. Pharmacological evaluation of prophylactic anti-asthma drugs by reference to the pathological sequelae of exposure to allergen or platelet activating factor. 1988 Agents Actions Suppl. pmid:3262989
Subissi A and Criscuoli M Effects of LG 30435 on different platelet activating factor-induced responses. 1988 Agents Actions Suppl. pmid:3262990
Heuer H and Casals-Stenzel J Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. 1988 Agents Actions Suppl. pmid:3262991
Anderson GP and Fennessy MR Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. 1988 Agents Actions Suppl. pmid:3140616
Bertrand C et al. Selective implication of thromboxane A2 and PAF-acether in two guinea pig anaphylactic models. 1990 Agents Actions Suppl. pmid:2080755
Tsunoda H et al. Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses. 1990 Agents Actions Suppl. pmid:2080757
Parnham MJ et al. Regulation of the oxidative burst of macrophages by lipid mediators. 1984 Agents Actions Suppl. pmid:6433680
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
Northover AM Modification by some antagonists of the shape changes of venous endothelial cells in response to inflammatory agents in vitro. 1990 Agents Actions pmid:2111079
McLeod J et al. Effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on substance P-induced histamine release from rat peritoneal mast cells. 1990 Agents Actions pmid:1695435
Adolfs MJ et al. PAF-acether modifies human peritoneal macrophage cAMP levels in a biphasic fashion. 1989 Agents Actions pmid:2540635
Bekemeier H and Sänze JU Vasodepression ex vivo after administration of inflammatory mediators in vivo in the rat. 1989 Agents Actions pmid:2476918
Jouquey S et al. Comparison of the effects of the ace inhibitors trandolapril and enalapril on phlogogen induced foot pad oedema in the rat. 1988 Agents Actions pmid:2459935
Sanchez Crespo M and Nieto ML Modulation of PAF biosynthesis in human polymorphonuclear leukocytes. The role of phorbol esters and protein kinases. 1989 Agents Actions pmid:2711927
Zijlstra FJ et al. The effects of PAF-acether and FMLP on eicosanoid production in guinea pig alveolar macrophages. 1989 Agents Actions pmid:2711928
Nijkamp FP et al. Role of platelet activating factor in the endotoxin induced tracheal hyperreactivity to histamine in the guinea pig. 1989 Agents Actions pmid:2711929
Oliver JL et al. Effect of PAF acether on oriented egg phosphatidylcholine multibilayers; interaction with cholesterol; comparison to lyso-PC and lyso-PAF. 1989 Agents Actions pmid:2711930
Nieminen MM et al. Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit. 1991 Agents Actions pmid:1862740
Jenei B et al. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). 1991 Agents Actions pmid:1862750
Kantar A et al. Effect of PAF on erythrocyte membrane heterogeneity: a fluorescence study. 1991 Agents Actions pmid:1862752
Carlson RP et al. Pharmacologic modulation of PAF-induced mortality in mice. 1987 Agents Actions pmid:3120513
Anderson GP et al. Increased airways responsiveness to histamine induced by platelet activating factor in the guinea-pig: possible role of lipoxygenase metabolites. 1988 Agents Actions pmid:3136622
Taira M et al. Lack of involvement of leukotriene and platelet activating factor in passive cutaneous anaphylaxis in rats. 1988 Agents Actions pmid:3407549
Kusner EJ et al. Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat. 1987 Agents Actions pmid:3577957
Northover AM In vitro effects of PAF on venous endothelial cell actin disposition. 1992 Agents Actions pmid:1509977
Benveniste J Platelet-activating factor (PAF-acether): present status. 1981 Agents Actions pmid:6176101
Meats JE et al. Identification of phospholipase D (PLD) activity in mouse peritoneal macrophages. 1993 Agents Actions pmid:8273553
Thomas TK et al. Differential antagonism of platelet activating factor-induced neutrophilia and gastric hemorrhage in the rat. 1993 Agents Actions pmid:8273566
Glaser KB et al. Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2). 1993 Agents Actions pmid:8273577